Annual report
8086.TEDINET S100OJBW
Period2021-04-01 → 2022-03-31
Filed2022-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥455.6bn | 2020-04-01 → 2021-03-31 | Cons. | Net sales |
| Revenue | ¥442.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥426.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥395.4bn | 2017-04-01 → 2018-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥23.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Operating income | ¥27.6bn | 2020-04-01 → 2021-03-31 | Cons. | Operating income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥26.3bn | 2020-04-01 → 2021-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥23.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.4bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.7bn | 2017-04-01 → 2018-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥17.5bn | 2020-04-01 → 2021-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.2bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥12.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥11.8bn | 2017-04-01 → 2018-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥15.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Net income | ¥15.0bn | 2020-04-01 → 2021-03-31 | Cons. | Profit loss |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥854.4bn | at 2021-03-31 | Cons. | Assets |
| Total assets | ¥831.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥845.8bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥826.4bn | at 2018-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Total liabilities | ¥680.3bn | at 2021-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥174.1bn | at 2021-03-31 | Cons. | Net assets |
| Net assets / equity | ¥161.2bn | at 2020-03-31d | Cons. | Net assets |
| Net assets / equity | ¥171.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥183.5bn | at 2018-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥90.3bn | at 2021-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥90.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥120.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥135.6bn | at 2018-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥66.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥37.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.0bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥45.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥58.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64.1bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.1bn | 2020-04-01 → 2021-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥4.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥12.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥47.3bn | 2017-04-01 → 2018-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.12 | 2020-04-01 → 2021-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-75.3 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.68 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥71.15 | 2017-04-01 → 2018-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.75 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥64.51 | 2017-04-01 → 2018-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥987.3 | at 2021-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥912.24 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥990.14 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,037.25 | at 2018-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.9% | at 2018-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | -7.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.0% | 2017-04-01 → 2018-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 36,259 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 35,251 | at 2021-03-31 | Cons. | Number of employees |
| Employees | 32,786 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 29,325 | at 2019-03-31d | Cons. | Number of employees |
| Employees | 28,330 | at 2018-03-31d | Cons. | Number of employees |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥334.9bn | 2020-04-01 → 2021-03-31 | Standalone | Net sales |
| Revenue | ¥340.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥310.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥270.8bn | 2017-04-01 → 2018-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥11.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Operating income | ¥12.4bn | 2020-04-01 → 2021-03-31 | Standalone | Operating income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.4bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.5bn | 2017-04-01 → 2018-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥14.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥11.8bn | 2020-04-01 → 2021-03-31 | Standalone | Income before income taxes |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2020-04-01 → 2021-03-31 | Standalone | Profit loss |
| Net income | −¥16.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.3bn | 2017-04-01 → 2018-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥727.0bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥695.1bn | at 2021-03-31 | Standalone | Assets |
| Total assets | ¥666.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥654.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥622.7bn | at 2018-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥547.2bn | at 2022-03-31 | Standalone | Liabilities |
| Total liabilities | ¥521.4bn | at 2021-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥179.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥173.7bn | at 2021-03-31 | Standalone | Net assets |
| Net assets / equity | ¥157.7bn | at 2020-03-31d | Standalone | Net assets |
| Net assets / equity | ¥171.0bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥172.9bn | at 2018-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.1bn | at 2022-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥16.0bn | at 2021-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.72 | 2020-04-01 → 2021-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-100.66 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.25 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.81 | 2017-04-01 → 2018-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥67.27 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.92 | 2017-04-01 → 2018-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28.5 | 2017-04-01 → 2018-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,065.15 | at 2021-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥966.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,048.54 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,039.12 | at 2018-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.0% | at 2021-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 27.8% | at 2018-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-04-01 → 2021-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | -10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.2% | 2017-04-01 → 2018-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2021-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2018-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,252 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,150 | at 2021-03-31 | Standalone | Number of employees |
| Employees | 4,060 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 3,893 | at 2019-03-31d | Standalone | Number of employees |
| Employees | 3,499 | at 2018-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥281m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥299m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2022-03-31 | 109 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥559m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥158.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥101m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥7.0bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥4.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥35.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥35.2bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥57.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥28.2bn |
| Medical Treatment Relatedreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥56.8bn |
| Medical Treatment Relatedreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥20.1bn |
| Medical Treatment Relatedreportable segment | employees | at 2022-03-31 | 25239 pure |
| Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥379.8bn |
| Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥373.5bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.4bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2022-03-31 | ¥541.9bn |
| Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥39.2bn |
| Medicine Relatedreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥23.4bn |
| Medicine Relatedreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥13.4bn |
| Medicine Relatedreportable segment | employees | at 2022-03-31 | 6904 pure |
| Medicine Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥95.0bn |
| Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥74.4bn |
| Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥20.6bn |
| Medicine Relatedreportable segment | segment assets | at 2022-03-31 | ¥203.7bn |
| Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥9.8bn |
| Pharma Packagingreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.3bn |
| Pharma Packagingreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4.8bn |
| Pharma Packagingreportable segment | employees | at 2022-03-31 | 3255 pure |
| Pharma Packagingreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥52.5bn |
| Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥46.4bn |
| Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.1bn |
| Pharma Packagingreportable segment | segment assets | at 2022-03-31 | ¥83.3bn |
| Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥89.5bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥38.3bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥527.3bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥494.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥33.1bn |
| —segment total | segment assets | at 2022-03-31 | ¥828.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥89.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥38.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥530.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥494.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥35.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥987.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2020-04-01 → 2021-03-31 | ¥127m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2020-04-01 → 2021-03-31 | ¥279m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2020-04-01 → 2021-03-31 | ¥2.3bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2020-04-01 → 2021-03-31 | ¥691m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥1.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2021-03-31 | ¥56.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2020-04-01 → 2021-03-31 | ¥376m |
| Reconciling Itemsreconciling | capex | 2020-04-01 → 2021-03-31 | ¥4.4bn |
| Reconciling Itemsreconciling | depreciation | 2020-04-01 → 2021-03-31 | ¥4.9bn |
| Reconciling Itemsreconciling | revenue | 2020-04-01 → 2021-03-31 | −¥32.4bn |
| Reconciling Itemsreconciling | revenue intersegment | 2020-04-01 → 2021-03-31 | −¥32.4bn |
| Reconciling Itemsreconciling | segment assets | at 2021-03-31 | ¥60.8bn |
| Reconciling Itemsreconciling | segment profit | 2020-04-01 → 2021-03-31 | −¥24.2bn |
| Medical Treatment Relatedreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥47.9bn |
| Medical Treatment Relatedreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥18.2bn |
| Medical Treatment Relatedreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥349.9bn |
| Medical Treatment Relatedreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥343.8bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥6.1bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2021-03-31 | ¥481.5bn |
| Medical Treatment Relatedreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥38.9bn |
| Medicine Relatedreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥20.9bn |
| Medicine Relatedreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥12.2bn |
| Medicine Relatedreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥90.9bn |
| Medicine Relatedreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥72.4bn |
| Medicine Relatedreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥18.5bn |
| Medicine Relatedreportable segment | segment assets | at 2021-03-31 | ¥187.8bn |
| Medicine Relatedreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥10.6bn |
| Pharma Packagingreportable segment | capex | 2020-04-01 → 2021-03-31 | ¥5.5bn |
| Pharma Packagingreportable segment | depreciation | 2020-04-01 → 2021-03-31 | ¥4.2bn |
| Pharma Packagingreportable segment | revenue | 2020-04-01 → 2021-03-31 | ¥44.8bn |
| Pharma Packagingreportable segment | revenue external | 2020-04-01 → 2021-03-31 | ¥38.7bn |
| Pharma Packagingreportable segment | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥6.2bn |
| Pharma Packagingreportable segment | segment assets | at 2021-03-31 | ¥68.1bn |
| Pharma Packagingreportable segment | segment profit | 2020-04-01 → 2021-03-31 | ¥2.0bn |
| —segment total | capex | 2020-04-01 → 2021-03-31 | ¥74.3bn |
| —segment total | depreciation | 2020-04-01 → 2021-03-31 | ¥34.7bn |
| —segment total | revenue | 2020-04-01 → 2021-03-31 | ¥485.6bn |
| —segment total | revenue external | 2020-04-01 → 2021-03-31 | ¥454.9bn |
| —segment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥30.8bn |
| —segment total | segment assets | at 2021-03-31 | ¥737.4bn |
| —segment total | segment profit | 2020-04-01 → 2021-03-31 | ¥51.5bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2020-04-01 → 2021-03-31 | ¥74.4bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2020-04-01 → 2021-03-31 | ¥35.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2020-04-01 → 2021-03-31 | ¥488.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2020-04-01 → 2021-03-31 | ¥455.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2020-04-01 → 2021-03-31 | ¥32.4bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2021-03-31 | ¥793.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2020-04-01 → 2021-03-31 | ¥51.9bn |
| Medical Treatment Relatedreportable segment | employees | at 2022-03-31 | 3325 pure |
| Medicine Relatedreportable segment | employees | at 2022-03-31 | 20 pure |
| Pharma Packagingreportable segment | employees | at 2022-03-31 | 155 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,095
| Item | Context | Value | Unit |
|---|---|---|---|
| Average number of temporary workers | Prior4YearInstant_NonConsolidatedMember | 208 | |
| Average number of temporary workers | Prior3YearInstant_NonConsolidatedMember | 217 | |
| Average number of temporary workers | Prior2YearInstant_NonConsolidatedMember | 217 | |
| Average number of temporary workers | Prior1YearInstant_NonConsolidatedMember | 231 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 257 | |
| Total shareholder return | Prior4YearInstant_NonConsolidatedMember | 0.997 | |
| Total shareholder return | Prior3YearInstant_NonConsolidatedMember | 0.946 | |
| Total shareholder return | Prior2YearInstant_NonConsolidatedMember | 0.854 | |
| Total shareholder return | Prior1YearInstant_NonConsolidatedMember | 0.914 | |
| Total shareholder return | CurrentYearInstant_NonConsolidatedMember | 0.732 | |
| Total return on share price index | Prior4YearInstant_NonConsolidatedMember | 1.159 | |
| Total return on share price index | Prior3YearInstant_NonConsolidatedMember | 1.100 | |
| Total return on share price index | Prior2YearInstant_NonConsolidatedMember | 0.996 | |
| Total return on share price index | Prior1YearInstant_NonConsolidatedMember | 1.415 | |
| Total return on share price index | CurrentYearInstant_NonConsolidatedMember | 1.443 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 25239 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 613 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 6904 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 202 | |
| Number of employees | CurrentYearInstant_jpcrp030000-asr_E02688-000PharmaPackagingReportableSegmentMember | 3255 | |
| Average number of temporary workers | CurrentYearInstant_jpcrp030000-asr_E02688-000PharmaPackagingReportableSegmentMember | 105 | |
| Number of employees | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 109 | |
| Average number of temporary workers | CurrentYearInstant_OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember | 4 | |
| Number of employees | CurrentYearInstant_CorporateSharedMember | 752 | |
| Average number of temporary workers | CurrentYearInstant_CorporateSharedMember | 52 | |
| Number of employees | CurrentYearInstant | 36259 | |
| Average number of temporary workers | CurrentYearInstant | 976 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 4252 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 257 | |
| Average age years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 40.7 | |
| Average length of service years information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 13.1 | |
| Average annual salary information about reporting company information about employees | CurrentYearInstant_NonConsolidatedMember | 6583000 | JPY |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 3325 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 196 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 20 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | － | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02688-000PharmaPackagingReportableSegmentMember | 155 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_jpcrp030000-asr_E02688-000PharmaPackagingReportableSegmentMember | 9 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 752 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember_CorporateSharedMember | 52 | |
| Number of employees | CurrentYearInstant_NonConsolidatedMember | 4252 | |
| Average number of temporary workers | CurrentYearInstant_NonConsolidatedMember | 257 | |
| Research and development expenses research and development activities | CurrentYearDuration | 18734000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 8577000000 | JPY |
| Research and development expenses research and development activities | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 10157000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration | 46560000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicalTreatmentRelatedReportableSegmentsMember | 17122000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02688-000MedicineRelatedReportableSegmentsMember | 22093000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_jpcrp030000-asr_E02688-000PharmaPackagingReportableSegmentMember | 4341000000 | JPY |
| Capital expenditures overview of capital expenditures etc | CurrentYearDuration_CorporateSharedMember | 3003000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| balance sheet identity | pass rounding |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |